SG10201806016VA - Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly - Google Patents

Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly

Info

Publication number
SG10201806016VA
SG10201806016VA SG10201806016VA SG10201806016VA SG10201806016VA SG 10201806016V A SG10201806016V A SG 10201806016VA SG 10201806016V A SG10201806016V A SG 10201806016VA SG 10201806016V A SG10201806016V A SG 10201806016VA SG 10201806016V A SG10201806016V A SG 10201806016VA
Authority
SG
Singapore
Prior art keywords
white matter
elderly
disease
leukoaraiosis
wmh
Prior art date
Application number
SG10201806016VA
Inventor
Wijk Nick Van
Robert Johan Joseph Hageman
Mehmet Cansev
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of SG10201806016VA publication Critical patent/SG10201806016VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

METHOD FOR REDUCING WHITE MATTER LESIONS, WHITE MATTER HYPERINTENSITIES (WMH), LEUKOARAIOSIS OR PERIVENTRICULAR WHITE MATTER DISEASE IN ELDERLY 5 The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white matter lesions, white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease in elderly not suffering from a neurodegenerative disorder, preferably non-demented 10 elderly and elderly not suffering from Alzheimer’s Disease. It was found that with the compositions according to the invention Nogo-A protein levels could be controlled, particularly suppressed or reduced. [No suitable figure] 15
SG10201806016VA 2014-01-31 2015-02-02 Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly SG10201806016VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2014/050058 WO2015115885A1 (en) 2014-01-31 2014-01-31 Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly

Publications (1)

Publication Number Publication Date
SG10201806016VA true SG10201806016VA (en) 2018-08-30

Family

ID=50073399

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201806016VA SG10201806016VA (en) 2014-01-31 2015-02-02 Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
SG11201707955XA SG11201707955XA (en) 2014-01-31 2015-02-02 Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201707955XA SG11201707955XA (en) 2014-01-31 2015-02-02 Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly

Country Status (5)

Country Link
US (1) US10675292B2 (en)
EP (1) EP3099327A1 (en)
CN (1) CN106163562A (en)
SG (2) SG10201806016VA (en)
WO (2) WO2015115885A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017069611A1 (en) * 2015-10-23 2017-04-27 N.V. Nutricia Nutritional product for decreasing phenylalanine levels in pku patients
WO2017069613A1 (en) 2015-10-23 2017-04-27 N.V. Nutricia Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
BR112019011310A2 (en) * 2016-12-09 2019-10-15 Balchem Corp essential nutrients and related methods
CN110869010A (en) * 2017-07-12 2020-03-06 N·V·努特里奇亚 Method for treating traumatic brain injury
WO2019013616A1 (en) 2017-07-12 2019-01-17 N.V. Nutricia Treatment of traumatic brain injury
TW202143952A (en) * 2020-04-13 2021-12-01 美商威望生命科學公司 Delivery methods for omega-3's and compositions for vitamins and minerals used to enhance visual acuity and mental development in the human body

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941586D1 (en) * 1998-07-31 2009-12-03 Massachusetts Inst Technology Use of uridine in combination with choline for the treatment of memory disorders
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
NL1019368C2 (en) * 2001-11-14 2003-05-20 Nutricia Nv Preparation for improving receptor performance.
ATE509624T1 (en) 2005-12-23 2011-06-15 Nutricia Nv COMPOSITION CONTAINING POLYUNSATURATED FATTY ACIDS, PROTEINS, MANGANEOUS AND/OR MOLYBDENES AND NUCLEOTIDES/NUCLEOSIDES, FOR THE TREATMENT OF DEMENTIA
NZ599748A (en) 2007-06-26 2013-11-29 Nutricia Nv Improving memory in subjects with mini-mental state examination of 24-26
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002148A1 (en) 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
CN101896119A (en) * 2007-11-02 2010-11-24 麻省理工学院 Uridine dietary supplementation compliance methods and use thereof
EP2222311B1 (en) * 2007-12-20 2013-03-27 N.V. Nutricia Liquid nucleotides/nucleosides-containing product
EP2554057A4 (en) * 2010-03-31 2013-12-18 Vegenat S A Enteral or oral food product intended, in particular, for nutrition and for the prevention and improvement of neurological alterations, neurodegenerative alterations or cognitive disorders
WO2012125020A1 (en) 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
WO2013066151A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
WO2013066152A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function

Also Published As

Publication number Publication date
WO2015115899A1 (en) 2015-08-06
WO2015115885A1 (en) 2015-08-06
CN106163562A (en) 2016-11-23
EP3099327A1 (en) 2016-12-07
SG11201707955XA (en) 2017-10-30
US20170157164A1 (en) 2017-06-08
US10675292B2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
SG10201806016VA (en) Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
SG10201907660YA (en) Use of short chain fatty acids in cancer prevention
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
MX2018004224A (en) Feedstock for 3d printing and uses thereof.
MX2021011946A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency.
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
EP3377118A4 (en) Methods for treating alzheimer's disease and related disorders
MX2019003805A (en) Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies.
MX2015000618A (en) Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation.
SG10201909412RA (en) Composition for suppressing muscular fatty change
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
EP3398614A4 (en) Agent for preventing and/or treating alzheimer's disease
MX2017008755A (en) Calcitonin analogues for treating diseases and disorders.
HK1243709A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
PL3352742T3 (en) Compositions comprising triterpenoids for the treatment of alzheimer's disease and parkinson's disease
EP3628008A4 (en) Compositions and methods for treating alzheimer's disease
MX2018004532A (en) Combination of trazodone and gabapentin for the treatment of pain.
EP3370714A4 (en) Compositions and methods for the treatment of fatty acid metabolism disorders
MX2017013453A (en) Use of (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3 -yl)(naphthalene-2-yl) methanone in the prevention and/or treatment of non-alcoholic steatohepatitis.
IL265911A (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
EP3585411A4 (en) Il-22bp compositions and method for the treatment of disease therewith
MX2018008206A (en) Modified thiolases capable of producing branched compounds and uses thereof.